knowledge -WSS

knowledge

author：fashion 2025-09-30 03:26:22 - browse：37

Sen. Bill Cassidy, R-La., listens during a Senate Health, Education, Labor, and Pensions Committee hearing. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Stefani Reynolds/The New York Times via AP

WASHINGTON — The top-ranking Republican on the Senate health committee is launching an investigation into two hospitals’ use of a government program that provides big drug discounts in return for serving low-income communities.

At the foundation of the debate over the so-called 340B program is whether Congress intended it to directly benefit low-income and uninsured patients or whether it was meant to help finance those hospitals, which could use the money as they see fit to add services.

Hospitals say they use the money to provide such services as free care for uninsured patients, free vaccinations, mental health clinics, and community health programs. But drugmakers have long argued that hospitals and chain pharmacies abuse the program and divert its cash flows to other uses. They also say the 340B program fuels the consolidation of health care systems as hospitals buy up private doctor practices to expand the 340B revenue stream.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： How to improve immunocompromised access to mAb treatments

focus

WSS

How to increase colonoscopy rates? Looks like an AI can help

At ASCO, AstraZeneca reports strong data for breast cancer drug

Telehealth startups turn to complex chronic diseases

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO: AstraZeneca says CAR

First recipient of genetically engineered pig kidney has died

hotspot

knowledge

explore

Apple is now the first public company to be valued at $3 trillion

How to improve immunocompromised access to mAb treatments

Trump demands the U.S. pay no more for drugs than other countries … again

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Moonlake's readout produced a cash windfall. Risks remain

ASCO: AstraZeneca says CAR

Malaria cases in Florida and Texas: Here’s what you need to know

Let's speed up science by embracing open access publishing

23andMe had bad news about my health. I wish a person had delivered it

Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

The Pandemic Treaty must support building strong health systems

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

CDC wastewater surveillance dashboard to track bird flu hotspots

focus

focus

focus

Wikipedia